Since the first use of streptomycin as an effective antibiotic drug in the treatment of tuberculosis, aminoglycoside antibiotics have been widely used against a variety of bacterial infections for over six decades. However, the pathways for aminoglycoside biosynthesis still remain unclear, mainly because of difficulty in genetic manipulation of actinomycetes producing this class of antibiotics. Gentamicin belongs to the group of 4,6-disubstituted aminoglycosides containing a characteristic core aminocyclitol moiety, 2-deoxystreptamine (2-DOS), and the recent discovery of its biosynthetic gene cluster in Micromonospora echinospora has enabled us to decipher its biosynthetic pathway. To determine the minimal set of genes and their functions for the generation of gentamicin A 2, the first pseudotrisaccharide intermediate in the biosynthetic pathway for the gentamicin complex, various sets of candidate genes from M. echinospora and other related aminoglycoside-producing strains were introduced into a nonaminoglycoside producing strain of Streptomyces venezuelae. Heterologous expression of different combinations of putative 2-DOS biosynthetic genes revealed that a subset, gtmB-gtmA-gacH, is responsible for the biosynthesis of this core aminocyclitol moiety of gentamicin. Expression of gtmG together with gtmB-gtmA-gacH led to production of 2-Nacetylparomamine, demonstrating that GtmG acts as a glycosyltransferase that adds N-acetyl-D-glucosamine (GLcNA) to 2-DOS. Expression of gtmM in a 2-N-acetylparomamine-producing recombinant S. venezuelae strain generated paromamine. Expression of gtmE in an engineered paromamine-producing strain of S. venezuelae successfully generated gentamicin A 2, indicating that GtmE is another glycosyltransferase that attaches D-xylose to paromamine. These results represent in vivo evidence elucidating the complete biosynthetic pathway of the pseudotrisaccharide aminoglycoside.
G
entamicin is an aminoglycoside antibiotic complex produced by various Micromonospora species (1). Aminoglycosides act by binding to the bacterial ribosome inhibiting protein synthesis and generating errors in the translation of the genetic code (2) . This class of antibiotics has been used clinically for the treatment of severe bacterial infections for Ͼ60 years, beginning with the use of streptomycin to treat tuberculosis (3) . However, the genetics underlying the biosynthesis of aminoglycosides, including gentamicin, still remains unclear. Structurally, gentamicin is a 4,6-disubstituted aminocyclitol composed of the core aminocyclitol moiety, 2-deoxystreptamine (2-DOS, 1a), which is decorated by purpurosamine and garosamine aminosugars at positions C-4 and C-6, respectively. In its therapeutic form, gentamicin comprises a complex of gentamicin C 1 , C 1a , and C 2 , which differ only in the degree of methylation of the C-6Ј position of the sugar attached at C-4 of 2-DOS (Fig. 1) . Other minor components of gentamicin are also produced by Micromonospora echinospora, including gentamicin A 2 (4a), the precursor from which other forms of gentamicin are derived (4) .
The recent discovery of gene clusters for biosynthesis of butirosin and neomycin in Bacillus circulans and Streptomyces fradiae, respectively, has facilitated genetic and biochemical studies on the biosynthesis of 4,5-disubstituted aminoglycosides (5) (6) (7) (8) (9) . Concurrently, the biosynthetic gene clusters relating to the 4,6-disubstituted aminoglycosides kanamycin, tobramycin, and gentamicin have been isolated from Streptomyces kanamyceticus, Streptomyces tenebrarius, and M. echinospora, respectively (10) (11) (12) (13) . However, little progress has been made to evaluate the proposed biosynthetic routes to these antibiotics, mainly because of difficulty in genetic manipulation of the producing microorganisms. Gentamicin-producing M. echinospora has innate resistance to most antibiotics precluding the use of standard Streptomyces cloning vectors displays low transformation efficiency (Ͻ10 Ϫ7 transformants per microgram of DNA) (14) . Current knowledge regarding the biosynthesis of 2-DOS containing aminoglycosides was recently reviewed, and most of cited works relied on in vitro studies of individual gene products (15) . When the biosynthetic route to the gentamicin complex was first predicted, it was based on isolation of metabolites from cell culture extracts and precursor feeding studies of blocked mutants (16, 17) . However, functional studies of gentamicin biosynthetic genes have not been possible, so that assignment of the roles of gene products has hitherto been based purely on amino acid sequence comparisons pending verification by direct experimental evidence.
We show here that heterologous expression of different combinations of genes from the gentamicin biosynthetic gene cluster (refs. 11 and 12: GenBank accession nos. AJ575934 and AY524043) in a nonaminoglycoside producing strain of S. venezuelae caused production of intermediates from the gentamicin biosynthetic pathway including 2-DOS (1a), 2Ј-N-acetylparomamine (2a), paromamine (3a), and the first pseudotrisaccharide, gentamicin A 2 (4a). This provided experimental evidence for assigning the functions of individual gene products, allowing us to recognize a complete biosynthetic pathway for generation of gentamicin A 2 . This work has established an efficient heterologous expression platform based on a genetically amenable streptomycete to dissect the biosynthetic pathways of other aminoglycoside antibiotics produced by less tractable actinomycetes.
Results and Discussion
Putative gentamicin biosynthetic genes, suggested by previous studies to encode the 2-DOS biosynthetic enzymes, two glycosyltransferases and a deacetylase, were amplified by PCR (8, 10, 18) and cloned into a thiostrepton-resistance vector, pSE34, under control of the ermE* promoter (19) . Plasmids harboring different sets of genes necessary for the biosynthesis of gentamicin and its intermediates were heterologously expressed in a mutant strain of S. venezuelae YJ003 that lacks the ability to biosynthesize its native deoxysugar (TDP-D-desosamine) (20) . The culture extracts from the resulting strains were analyzed by using HPLC-ESI-MS/MS to detect gentamicin-related compounds, the structures of which were then further identified by comparison of the retention times, MS/MS fragmentation patterns, and NMR spectra with those obtained from authentic reference compounds.
A Minimal Set of Genes Necessary and Sufficient for 2-Deoxystreptamine Biosynthesis. Gentamicin biosynthesis begins with D-glucose-6-phosphate (Glc-6-P), which is modified to 2-deoxyscyllo-inosose (2-DOI) by carbocyclization through the action of GtmA, as described in ref. 12 . Two aminotransferase reactions and a dehydrogenase step are then required for the conversion of 2-DOI via 2-deoxy-scyllo-inosamine (2-DOIA) and 1-keto-2-deoxy-scyllo-inosamine (keto-2-DOIA) to produce 2-DOS (1a) (21) (22) (23) (24) (Fig. 1) . Based on an earlier study isolating the gentamicin biosynthetic gene cluster (11, 12) , we cloned the gtmDgtmB-gtmA-gtmC genes, which encode the inosose synthase (GtmA) and putative aminotransferases (GtmB and GtmD), plus the deduced dehydrogenase (GtmC), and expressed them in the heterologous host S. venezuelae YJ003 using pYJ494 in what proved to be an unsuccessful attempt to biosynthesize 2-DOS (1a). This negative result prompted us to replace gtmC with gacH (otherwise known as gntP), which locates between gtmK and gacI within the gentamicin biosynthetic gene cluster, following the prediction (15) that GacH might be the dehydrogenase involved in 2-DOS biosynthesis, based on its sequence homology to the 2-DOIA dehydrogenase Neo5 [CAH58688, otherwise known as NeoA (BAD95818)] involved in neomycin biosynthesis. When the resultant plasmid pYJ495 harboring gtmD-gtmB-gtmA-gacH was expressed in the heterologous host, 2-DOS (1a) was indeed produced (Fig. 2A) . The two transamination reactions required for biosynthesis of 2-DOS during butirosin production by B. circulans are catalyzed by a single enzyme, BtrS [BAE07061, otherwise known as BtrR (CAD41947)] (23). To ascertain whether the biosynthesis of 2-DOS during gentamicin production likewise involves dual activity of a single aminotransferase, two separate constructs pYJ496 and pYJ497 expressing gtmBgtmA-gacH and gtmD-gtmA-gacH, respectively, were tested. The expression of gtmB, gtmA, and gacH produced Ϸ120 g per liter of 2-DOS (1a) (corrected for Ϸ40% mean recoveries of 1a), whereas, gtmD, gtmA, and gacH did not do so ( Fig. 2 B and C) , indicating that GtmB catalyzes both transamination steps in the synthesis of 2-DOS, whereas GtmD may act in a later step during gentamicin production. The lower recoveries (Ͻ50%) of both 2-DOS (1a) and 2Ј-N-acetylparomamine (2a) were observed compared with those of other biosynthetic intermediates of gentamicin, probably because of their weak adsorption on the solid-phase extraction (SPE) cleanup column during analysis (25) . The predicted products of gtmA, gtmB, and gacH are similar to those of other 2-DOS (1a) biosynthetic genes from several 4,5-and 4,6-disubstituted aminoglycoside producers [see supporting information (SI) Figs. S1-S3 and SI Text]. Interestingly, the deduced product of gacH, which contains two zinc-binding motifs found in the NAD(P)-dependent dehydrogenase NeoA (Neo5) (22) , does not show sequence similarity to the recently characterized AdoMet-dependent dehydrogenase BtrN (24) , suggesting that GacH belongs to the NAD(P)-dependent dehydrogenase family (see Fig. S3 ).
Conferring Gentamicin Resistance in the Heterologous Host. A prerequisite for the biosynthesis of gentamicin in a heterologous host is self-protection of the host strain. To confer resistance to gentamicin in S. venezuelae, a plasmid, pYJ489, harboring three putative resistance genes (gtmF-gtmL-gtmK), was introduced into this mutant strain. The resistance genes gtmF and gtmL were chosen based on their ability to confer gentamicin resistance via specific methylation of the bacterial ribosomes without modify- ing the antibiotic itself (11) . The gtmK gene presumably encodes a transport protein involved in the export of aminoglycosides (11) . Transformants harboring pYJ489 were resistant to 100 g/ml of the commercially available gentamicin sulfate compared with Ϸ1 g/ml in control strains. The cell culture was extracted and analyzed for gentamicin components, and any of their derivatives (but only unmodified gentamicins) were recovered. These resistance determinants were expressed together with the gentamicin biosynthetic genes in the heterologous host in subsequent experiments.
GtmG Acts as an UDP-GlcNAc Glycosyltransferase to Generate 2-NAcetylparomamine (2a). Two glycosylation steps each involving NDP sugar cosubstrates are proposed to be required for gentamicin biosynthesis: the addition of D-glucosamine (GlcN) to form the pseudodisaccharide intermediate paromamine (3a), and the subsequent addition of D-xylose to form gentamicin A 2 (4a) (Fig. 1) . Two glycosyltransferases genes (gtmE and gtmG) identified within the gentamicin gene cluster (12) were expressed separately in the heterologous host to determine their roles. First, pYJ498 was constructed containing gtmG together with the 2-DOS biosynthetic genes (gtmB-gtmA-gacH) plus the resistance genes (gtmF-gtmK-gtmL). However, transformants containing pYJ498 did not synthesize paromamine (3a) but instead produced Ϸ105 g/liter of 2Ј-N-acetylparomamine (2a) (corrected for Ϸ40% mean recoveries of 2a) (Fig. 2D) . In contrast, transformants harboring pYJ499, derived from pYJ498 by replacement of gtmG by gtmE, produced neither 2Ј-N-acetylparomamine (2a) nor paromamine (3a). It therefore seemed plausible that GtmG might be accepting NDP-GLcNA rather than NDP-GlcN as the cosubstrate for attachment to 2-DOS (1a). This was confirmed by using cell-free extracts from the recombinant S. venezuelae because of difficulties in obtaining soluble GtmG protein by using standard expression systems. The crude cell-free extracts of the strain harboring pYJ498 were prepared and incubated with different concentrations of exogenous UDPGLcNA. The amount of 2Ј-N-acetylparomamine (2a) formed was elevated up to 4-fold as the input of UDP-GLcNA increased ( Fig. 3 A-C) . As expected, in vitro experiment using the same cell-free extracts supplemented with UDP-GlcN at the respective concentrations did not result in the production of paromamine (data not shown). It has been suggested by others (15) that a putative UDP-GLcNA glycosyltransferase gene, btrM (from the butirosin gene cluster) and its homologues (neo8, kanF, and gtmG from neomycin, kanamycin, and gentamicin biosynthetic gene clusters, respectively; sequence alignment of the predicted amino acid sequences of these genes is illustrated in Fig. S4 ) encode enzymes that catalyze the transfer of UDPGLcNA to 2-DOS (1a) to give 2Ј-N-acetylparomamine (2a). Although those other enzymes have yet to be functionally characterized using purified proteins, our present results strongly suggest that GtmG is indeed a UDP-GLcNA glycosyltransferase, which is a previously uncharacterized enzyme involved in the formation of pseudodisaccharide intermediate during aminoglycoside biosynthesis.
GtmM Acts as a 2-N-Acetylparomaine Deacetylase to Generate Paromaine (3a)
. During the biosynthesis of butirosin, a paromamine deacetylase, BtrD, acts on 2Ј-N-acetylparomamine (2a) to produce paromamine (3a) (18) , and a similar activity is required during the biosynthesis of gentamicin. A homologue of btrD is found in the region flanking either side of genD from the extended gentamicin biosynthetic gene cluster (GenBank accession no. AJ628149). Detailed sequence analysis revealed a possible start codon 142 nt upstream of genD gene. Further DNA sequencing of the PCR product of the ORF-corrected genD found the insertion of single cytosine residue at the 51th nucleotide position in genD, causing the frame shift in the coding region. A new ORF (gtmM, GenBank accession no. AM946392) encoding putative deacetylase is located 11,096 nt downstream of gacH. When the deduced product of gtmM was aligned with those of the well characterized deacetylases, two highly conserved regions (HXDD and HXDH) (18) were evident (see Fig.  S5 ). We imported the deacetylase genes btrD, kacA, neo16, and gtmM from the gene clusters for butirosin, kanamycin, neomycin, and gentamicin biosynthesis, respectively (5, 6, 10) . The four deacetylase genes were separately cloned into constructs containing the genes for 2-DOS biosynthesis, glycosyltransfer, and resistance (gtmB-gtmA-gacH-gtmF-gtmG-gtmK-gtmL) to produce plasmids pYJ500, pYJ501, pYJ502, and pYJ503, respectively. Expression of all four plasmids in the heterologous host led to production of paromamine (3a) along with its precursor 2Ј-N-acetylparomamine (2a) (Fig. 2E ). Strains expressing the Streptomyces genes kacA, neo16, and gtmM biosynthesized similar amounts of paromamine (3a) (150 g per liter, corrected for Ϸ90% mean recoveries of 3a), whereas slightly lower amounts were obtained with btrD, which is of Bacillus origin and might have been expressed less efficiently in the heterologous host, S. venezuelae. These results verify KacA, Neo16, and GtmM as deacetylases involved in the biosynthesis of paromamine (3a) and are in agreement with the previous report that paromamine (3a) is produced via the intermediate 2Ј-N-acetylparomamine (2a) using His 6 -tagged BtrD (18) . Here, we produced both 2Ј-N-acetylparomamine (2a) and paromamine (3a) in vivo, which reveals that 2Ј-N-acetylparomamine (2a) is a true biosynthetic intermediate in the formation of gentamicin and other aminoglycosides.
GtmE Acts as an UDP-Xylose Glycosyltransferase to Generate Gentamicin A2 (4a).
A second glycosylation, using NDP-D-xylose (NDPXyl) as cosubstrate, is required for the formation of gentamicin A 2 (4a) from paromamine (3a). Expression of gtmE with the genes necessary for biosynthesis of paromamine (gtmB-gtmAgacH-gtmF-gtmG-kacA/gtmM-gtmK-gtmL) led to production of gentamicin A 2 (4a) together with its precursors 2Ј-Nacetylparomamine (2a) and paromamine (3a) (Fig. 2F ). Therefore, GtmE appears to be the glycosyltransferase required for the transfer of NDP-Xyl to paromamine (3a). Sequence alignment of the predicted product of gtmE with other putative glycosyltransferases, which are found in the biosynthetic gene clusters of other 4,6-disubstituted aminoglycosides, is shown in Fig. S6 . The yield of gentamicin A 2 (4a) obtained from the culture extract was only 4.5 g/liter (corrected for Ϸ95% mean recoveries of 4a), and a substantial amount of paromamine (3a) remained unaltered, suggesting that NDP-Xyl might be present in S. venezuelae in limiting amounts. To determine whether D-xylose is attached directly to paromamine or whether D-xylose is generated from glucose or ribose, whereas they are bound to paromamine (26), crude cell-free extracts from the strain harboring pYJ504 were prepared and incubated with different concentrations of exogenous UDP-Xyl and UDP-glucose (UDP-Glc). Increased input of UDP-Xyl resulted in enhanced production of gentamicin A 2 up to 8-fold (4a), whereas in reciprocal fashion the amount of residual paromamine (3a) dropped significantly (Fig. 3 D-F) . However, UDP-Glc did not support biosynthesis of gentamicin A 2 . Although NDP-ribose could not be tested because of its unavailability, these results provide evidence that UDP-D-xylose (UDP-Xyl) is a cofactor for gentamicin A 2 biosynthesis, and that its transfer to paromamine is catalyzed by GtmE. It was reported (27) that an UDP-glucuronic acid (UDP-GlcA) decarboxylase AviE2 was involved in the formation of UDP-Xyl in avilamycinproducing Streptomyces viridochromogenes Tu57 (27) . CalS8 of calicheamicin-producing M. echinospora was reported as an UDP-Glc dehydrogenase involved in deoxypentose biosynthesis. Furthermore, several natural products such as maduropeptin from Actinomadura madurea, esperamicin from Actinomadura verrucosospora, and evernimicin from Micromonospora carbonacea bear deoxypentose(s) (28) . UDP-Glc dehydrogenase and UDP-GlcA decarboxylase may be the key enzymes necessary to synthesize nucleotide-activated deoxypentoses such as UDP-Xyl in actitomycetes in a similar way to plants and fungi (29, 30) , and it seems likely that such metabolic pathways are present in S. venezuelae to provide NDP-Xyl.
In conclusion we have elucidated the minimal complement of genes required for the formation of gentamicin A 2 and identified its biosynthetic intermediates. 2-DOS (1a) is synthesized by the products of gtmB, gtmA, and gacH. The gtmG gene encodes a glycosyltransferase that transfers GLcNA to produce 2Ј-Nacetylparomamine (2a). A deacetylase GtmM required to remove the acetyl group to form paromamine (3a) was found in M. echinospora, and GtmM and its homologues BtrD, KacA, and Neo16 were each able to carry out this function. GtmE attaches D-xylose to paromamine (3a) to produce gentamicin A 2 (4a). The constructed gene combinations and the obtained biosynthetic intermediates are shown in Table 1 . The assigned functions of these genes are summarized in Table 2 . This report represents an in vivo study regarding the expression of biosynthetic enzymes for complete synthesis of the pseudotrisaccharide form of an aminoglycoside in a heterologous host. Direct evidence is provided for the biosynthetic route to this 4,6-disubstituted aminoglycoside allowing the unequivocal assignment of specific gene products to each biosynthetic step. Further studies regarding the in vitro characterization of both glycosyltransferases, GtmG and GtmE, toward their substrates are impending. A detailed understanding of the complete biosynthetic pathway of gentamicin C components would assist in comprehending the biosynthesis of other 4,6-disubstituted aminoglycosides and form the basis for evolution of pathway engineering toward the generation of aminoglycosides active against rapidly emerging aminoglycoside-resistant pathogens. A continuing challenge of this heterologous expression approach is the relatively low productivity of the target compounds. However, understanding the limited intracellular availability of one cosubstrate (NDP-D-xylose) provided a strategy for enhancing the production level.
Materials and Methods
Bacterial Strains, Plasmids, and Culture Conditions. Escherichia coli DH10B and plasmid Litmus28 (New England Biolabs) were used for routine subcloning. High-copy number E. coli-Streptomyces shuttle vector pSE34 containing the strong ermE* promoter plus a thiostrepton resistance marker was used as an expression plasmid (19) . The gentamicin biosynthetic genes from M. echinospora are located on the cosmid pGEN01 (12) . S. venezuelae YJ003, which is deficient in biosynthesis of the endogenous deoxysugar TDP-D-desosamine, was used as a heterologous host (20) . Protoplast formation and transformation procedures of S. venezuelae were performed as described (31) . S. venezuelae YJ003 and derived strains were maintained on SPA agar (20) and grown in liquid R2YE (31) at 30°C for preparation of protoplasts, which were regenerated on R2YE agar medium supplemented with thiostrepton (30 g/ml). The E. coli strains were grown in LB medium supplemented with ampicillin (50 g/ml) to select for plasmid vectors. For production of gentamicin intermediates, S. venezuelae strains expressing gentamicin biosynthetic genes were cultivated at 30°C for 4 days in one liter of baffled Erlenmeyer flasks containing 300 ml of R2YE medium supplemented with thiostrepton (25 g/ml). To obtain authentic gentamicin A2, M. echinospora ATCC 15385 was grown for 7 days at 28°C in 50 ml of N-Z amine medium (1% glucose, 2% soluble starch, 0.5% yeast extract, 0.5% N-Z amine and 0.2% calcium carbonate) in 500-ml baffled flasks on a rotary shaker (25) .
PCR Amplification of Gentamicin Biosynthetic
Genes. DNA fragments containing various gentamicin biosynthetic genes were amplified by PCR (Table S1 ). Each pair of deoxyoligonucleotide primers contained two restriction sites to facilitate subcloning of each DNA fragment. PCR was performed by using Pfu polymerase (Fermentas) under the manufacturer's recommended conditions. The DNA fragments containing each of gtmF, gtmK, gtmL, gtmD, gtmB, gtmA, gtmC, gacH, gtmG, and gtmE were amplified by using pGEN01 as a template (12) . The fragments encoding GtmM, BtrD, KacA, and Neo16 were amplified by using genomic DNA from M. echinospora ATCC 15385, Bacillus circulans ATCC 21557, S. kanamyceticus ATCC 12853, and S. fradiae ATCC 10745, respectively, due to template. All PCR products were cloned into Litmus28 and sequenced to confirm their authenticity.
Construction of Expression Plasmids.
This was done as summarized in Table 1 . Amplified products of the putative resistance genes gtmF-gtmK-gtmL were ligated in series into pSE34 by using standard protocols, and the resultant plasmid, pYJ489, was used to confer gentamicin resistance in S. venezuelae.
For expression of a combination of putative 2-DOS (1a) biosynthetic genes, PCR-amplified fragments containing gtmD, gtmB, gtmA, gtmC, or gacH were ligated in series into Litmus28 and then transplanted into pSE34 to generate a set of plasmids containing gtmD-gtmB-gtmA-gtmC, gtmD-gtmB-gtmAgacH, gtmB-gtmA-gacH, and gtmD-gtmA-gacH. These were designated pYJ494, pYJ495, pYJ496, and pYJ497, respectively. In a further set of constructions, the resistance genes gtmF-gtmK-gtmL from pYJ489 were introduced into pYJ496 together with either of the glycosyltransferase genes gtmG or gtmE to generate pYJ498 or pYJ499, respectively. The latter two vectors allowed expression of 2-DOS biosynthetic genes and gentamicin resistance determinants in addition to the respective glycosyltransferase genes. The next set of expression vectors, pYJ500, pYJ501, pYJ502, and pYJ503, were equivalent to pYJ498 supplemented with deacetylase genes btrD, kacA, neo16, and gtmM, respectively, and finally introduction of gtmE into gtmG-containing pYJ501 and pYJ503 generated a plasmid, pYJ504 and pYJ505, respectively, capable of expressing the entire complement of resistance determinants plus the minimal gene set for gentamicin A2 production.
Analyses of Gentamicin Biosynthetic
Intermediates. Gentamicin biosynthetic intermediates produced by S. venezuelae strains were extracted by using the OASIS MCX (Waters) SPE cleanup procedure was done as described (25) and analyzed by HPLC-ESI-MS/MS. Analytical HPLC-ESI-MS/MS was performed on a Waters/Micromass Quattro micro/MS interface using two XTerra MS C 18 (3.5 m, Waters) columns, 150 ϫ 2.1 and 250 ϫ 2.1 mm, connected in tandem. The analytes were eluted at a flow rate of 60 l/min with 30% (vol/vol) acetonitrile in water with 10 mM heptafluorobutyric acid (HFBA, Fluka) and monitored by ESI in the positive mode. Quantification of the analytes was conducted by using MS/MS in the multiple reactions monitoring mode. This was done by selecting the two mass ions set to detect a transition of the parent ion to the product ion specific to the selected analytes (26): 2-DOS (1a), 163 Ͼ 102; 2Ј-N-acetylparomamine (2a), 366 Ͼ 163; paromamine (3a), 324 Ͼ 163; gentamicin A 2 (4a), and 456 Ͼ 163. Five separate cultivations and extractions were performed.
Isolation and Identification of Gentamicin Biosynthetic
Intermediates as Authentic Standards. 2-DOS (1a) produced by S. venezuelae strains was identified by using commercially available 2-DOS (1a) (GeneChem) as a standard. 2Ј-Nacetylparomamine (2a) was purified directly from an S. venezuelae strain harboring the plasmid pYJ498, and its spectral data were authenticated by comparison with previous data (18) . Paromamine (3a) from S. venezuelae expressing plasmid pYJ501 was identified by using standard material obtained from hydrolysis of paromomycin (Sigma). Gentamicin A 2 (4a) produced by S. venezuelae harboring pYJ504 was compared with its purified form from wild-type M. echinospora. Details for the preparation and analysis of both authentic standards and gentamicin biosynthetic intermediates produced by S. venezuelae strains harboring the respective gene sets are given in SI Text; see also Figs. S7-S14 Tables S2-S5. Preparative HPLC was performed with a Spherisorb S5 ODS2 (250 ϫ 20 mm, Waters) semiprep column eluted with the same mobile phase used in the analytical HPLC system, at a flow rate of 12 ml/min over a period of 100 min. This eluent was fractionated into 5-ml portions that were monitored by analytical HPLC-ESI-MS/MS to detect and characterize the presence of gentamicin biosynthetic intermediates. Fractions containing products of interest were pooled and extracted by using OASIS MCX SPE cleanup (25) followed by freeze-drying. 1 H, 13 
*Using pSE34 E. coli-Streptomyces shuttle vectors (19) . † 1a, 2a, 3a, and 4a representing 2-deoxystreptamine, 2'-N-acetylparomamine, paromamine, and gentamicin A2, respectively. 2'-N-Acetylparomamine deacetylase This work NMR spectra were acquired by using a Varian INOVA 500 spectrometer at 298 K. Chemical shifts were reported in ppm by using trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) as an internal reference. The assignment of each compound was carried out by comparison with previously assigned 1 H NMR spectra (18, (32) (33) (34) and by a combination of 1D and 2D NMR experiments. All NMR data processing was done by using MESTREC (Magnetic Resonance Companion) software.
In Vitro Glycosyltransfer Reactions Using Cell-Free Extracts. Cell-free extracts of S. venezuelae strains harboring pYJ498 or pYJ504 were prepared by glassbead homogenization (31) . The mycelium (6-g wet weight) of each strain had been cultivated in R2YE medium for 3 days at 30°C, harvested by centrifugation, washed twice with 0.1 M Tris⅐HCl (pH 7.6), and then resuspended in 20 ml of extraction buffer (0.1 M Tris⅐HCl, 10 mM MgCl 2, 6 mM 2-mercaptoethanol, 1 mM PMSF, pH 7.6) at 4°C. After mixing with 10 g of precooled glass beads (150 to 212 m in diameter, Sigma), the mycelium was disrupted by vigorous agitation by using a vortex mixer. This involved 10 bursts of 30 sec each, with intermittent cooling in ice. Next, the glass beads were eliminated by lowspeed centrifugation, and cellular debris was removed by centrifugation at 18,000 ϫ g for 20 min. The entire process was carried out at 4°C and generated 15 ml of resulting supernatant. As one of proposed substrates for GtmG reaction, UDP-GlcN was prepared by enzymatic reaction of UDP-D-glucose pyrophosphorylase (E.C. 2.7.7.9, Sigma) with glucosamine-1-phosphate (Sigma) and UTP (Sigma), as described in ref. 35 . Glycosyltransfer reactions were initiated by adding activated sugar cosubstrates to the cell-free extracts as follows: for GtmG, UDP-GLcNA (GeneChem) or UDP-GlcN was used at final concentrations between 0 and 0.55 mM; for GtmE, UDP-D-xylose (CarboSource Services, University of Georgia, Griffin, GA) or UDP-Glc (Sigma) was used at final concentrations between 0 and 0.60 mM. Reaction mixtures were incubated at 30°C for 10 h before quenching with 15 ml of ice-cold phenol/ chloroform/isoamyl alcohol (25:24:1, Sigma). After centrifugation, gentamicin-related compounds were extracted by using OASIS MCX SPE cleanup as previously described and then reconstituted to 200 l with water. A portion of each extract was subjected to HPLC-ESI-MS analysis (see conditions described above). Independent experiments were performed in duplicate. , 1a) was purchased from GeneChem (Republic of Korea) and used without further purification. Fifteen liters of culture broth from S. venezuelae strain harboring pYJ496 were treated as described in Materials and Methods in the main text to prepare 1a as a white solid (1.5 mg). Based on comparisons of the retention time, MS/MS and NMR spectra with those of the 2-DOS (1a) authentic standard, a compound produced by S. venezuelae strains harboring plasmids expressing the gtmB-gtmA-gacH genes (pYJ495 and pYJ496) was found to be 2-DOS (1a) (see the analytical data of 1a described below). Eighteen liters of culture broth obtained from combining numerous batch cultivations of S. venezuelae strain harboring pYJ498 were treated as described in Materials and Methods to prepare 2Ј-N-acetylparomamine (2a) as a pale yellow solid (1.3 mg). By comparing the assigned NMR data with the data acquired by Truman et al. (5) and interpretations of MS/MS spectra based on cross-referencing with spectra of various gentamicin intermediates obtained in our previous study (6) , a compound produced by S. venezuelae strains harboring plasmid expressing gtmB-gtmA-gacH-gtmG and resistance genes (pYJ498) was identified as 2Ј-N-acetylparomamine (2a) (see the analytical data of 2a described below).
Supporting Information
Paromamine (3a) was chemically synthesized by acid hydrolysis of paromomycin (Sigma) as described previously (7). The hydrolysate was titrated to pH 6 and purified using SPE cartridge, then freeze-dried to produce the authentic paromamine. The NMR data of the authentic paromamine prepared was consistent with the previous report (3) . Nine liters of culture broth from S. venezuelae strain harboring pYJ501 were treated as described in Materials and Methods to prepare 3a as a white solid (3.2 mg). By comparing the retention time, MS/MS and NMR spectra with those of authentic paromamine, a compound produced by mutant strains harboring plasmids containing the gtmB-gtmA-gacH-gtmG-btrD/kacA/neo16/gtmM genes (pYJ500, pYJ501, pYJ502, and pYJ503) was determined to be paromamine (3a) (see the analytical data of 3a described below).
Authentic gentamicin A 2 (4a) was isolated and purified from the extract of wild-type M. echinospora ATCC 15835 as described in Materials and Methods. The NMR data of the authentic gentamicin A 2 prepared were consistent with the previous report (8, 9) . Fifteen liters of culture broth obtained from combining numerous batch cultivations of S. venezuelae strain harboring pYJ504 were treated as described in Materials and Methods. As well, 10 separate in vitro reactions using the cell-free extracts of mycelium obtained from the corresponding culture were carried out, and then pooled into the above extracts to prepare gentamicin A 2 (4a) as a pale yellow solid (0.5 mg). By comparison of the retention time, MS/MS and partially assigned NMR spectra with those of authentic gentamicin A 2 purified from wild-type M. echinospora (6, 8, 9) , a compound produced from S. venezuelae strain harboring pYJ504 and pYJ505 containing the gtmB-gtmAgacH-gtmG-gtmE-kacA and resistance genes was identified as gentamicin A 2 (4a) (see the analytical data of 4a described below). All NMR samples were prepared by dissolving each compound in 150 l of D 2 O and placing the solution in a 5 mm Shigemi advanced NMR microtube matched to the solvent. . S7 ); 1 H and 13 C NMR data of 1a were described in Table S2 and Fig. S8 . Fig. S9 ); 1 H and 13 C NMR data of 2a were described in Table S3 and Fig. S10 . Fig. S11 ); 1 H and 13 C NMR data of 3a were described in Table S4 Fig. S13) ; 1 H and 13 C NMR data of 4a were described in Table S5 and Fig. S14. Fig. S1 . Sequence alignment of GtmA with other 2-deoxy-scyllo-inosose synthases from S. kanamyceticus (KanA: GenBank accession no. CAE46939, or KanC: CAF31589), S. tenebrarius (TbmA: CAE22471, or TobC: CAH18556), S. fradiae (NeoC: BAD95820, or Neo7: CAH58690), and Bacillus circulans (BtrC: BAE07067). Multiple alignment of each sequence was carried out by ClustalX (1). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ80% homology. Black letters in light gray boxes represent residues with Ϸ60% homology. The predicted product of gtmA (397 aa) is 57% identical to KanA (KanC), 58% identical to TbmA (TobC), 56% identical to NeoC (Neo7), and 38% identical to BtrC.
2-Deoxystreptamine (1a

2-N-acetylparomamine (2a). T retention (HPLC-ESI-MS
M(ab)ϩH] 366, [M(ab)ϩH- 3H 2 O-2NH 3 ] 288, [M(ab)ϩH-4H 2 O-2NH 3 ] 270, [M(ab)ϩH- 5H 2 O-CH 3 ] 241, [M(a)ϩH] 204, [M(a)ϩH-H 2 O] 186, [M(a)ϩH-2H 2 O] 168, [M(b)ϩH] 163, [M(b)ϩH-H 2 O] 145, [M(a)ϩH-2H 2 O-C 2 H 2 ϩH 2 ] 144, [M(b)ϩH-2H 2 O] 126, [M(b)ϩH-4H 2 O-C 2 H 2 ϩH 2 ] 84 (seeM(ab)ϩH-NH 3 -2H 2 O] 271, [M(ab)ϩH-NH 3 -4H 2 O-C 2 H 2 ϩH 2 ] 211, [M(ab)ϩH-NH 3 - 4H 2 O-2C 2 H 2 ϩ2H 2 ] 187, [M(b)ϩH] 163, [M(b)ϩH-H 2 O] 145, [M(b)ϩH-2H 2 O] 126, [M(b)ϩH-H 2 O-NH 3 -C 2 H 2 ] 102, [M(b)ϩH-2H 2 O-NH 3 -C 2 H 2 ] 84, [M(b)ϩH-2H 2 O-NH 3 - 2C 2 H 2 ϩH 2 ] 60 (seeM(abc)ϩH] 456, [M(abc)ϩH-NH 3 ] 438, [M(abc)ϩH-NH 3 -H 2 O] 421, [M(ab)ϩH] 324, [M(ab)ϩH-NH 3 ] 307, [M(bc)ϩH] 295, [M(bc)ϩH-H 2 O] 277, [M(bc)ϩH-H 2 O- C 2 H 2 ϩH 2 ] 253, [M(bx)ϩH] 205, [M(bx)ϩH-H 2 O] 187, [M(b)ϩH] 163, [M(b)ϩH-H 2 O] 145, [M(b)ϩH-2H 2 O-NH 3 -C 2 H 2 ] 84 (see
Fig. S2.
Sequence alignment of GtmB with other L-glutamine:2-deoxy-scyllo-inosose aminotransferases from S. kanamyceticus (KanB: GenBank accession no. CAE46938, or KanS1: CAF31588), S. tenebrarius (TbmB: CAE22472, or TobS1: CAH18555), S. fradiae (NeoB: BAD95819, or Neo6: CAH58689), and Bacillus circulans (BtrR: CAD41947, or BtrS: BAE07061). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ80% homology. Black letters in light gray boxes represent residues with Ϸ60% homology. The predicted product of gtmB (463 aa) is 60% identical to KanB (KanS1), 62% identical to TbmB (TobS1), 60% identical to NeoB (Neo6), and 41% identical to BtrR (BtrS).
Fig. S3.
Sequence alignment of GacH with other 2-deoxy-scyllo-inosamine dehydrogenases from S. kanamyceticus (KanK: GenBank accession no. CAE46938, or KanE: CAF31584), S. tenebrarius (TacD: CAE22477, or TobE: CAH18550), S. fradiae (NeoA: BAD95818, or Neo5: CAH58688), and Bacillus circulans (BtrN: CAD41948). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ80% homology. Black letters in light gray boxes represent residues with Ϸ60% homology. The predicted product of gacH (341 aa) is 45% identical to KanK (KanE), 47% identical to TacD (TobE), and 48% identical to NeoA (Neo5). However, it does not show sequence similarity to the recently characterized SAM dependent dehydrogenase BtrN (2) . NeoA (Neo5) is characterized as a zinc-containing NAD(P) dependent dehydrogenase, which includes two zinc-binding motifs (3), and our sequence analysis also indicated the same two motifs observed in NeoA are also present in GacH (catalytic zinc ion coordination residues Cys-41, His-63, Glu-64, Glu-147, and Pro-148; structural zinc coordination Cysteins at 92, 95, 98, and 106 positions).
Fig. S4.
Sequence alignment of GtmG with other glycosyltransferases from S. kanamyceticus (KanM1: GenBank accession no. BAE95600, or KanF: CAE46947), S. tenebrarius (TobM1: CAH18562), S. fradiae (Neo8: CAH58691 or NeoD: AB211959), and Bacillus circulans (BtrM: CAG77417). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ80% homology. Black letters in light gray boxes represent residues with Ϸ60% homology. The predicted product of gtmG is 54% identical to KanM1 (KanF), 57% identical to TobM1, 53% identical to Neo8, and 37% identical to BtrM.
Fig. S5
. Sequence alignment of GtmM (GenBank accession no. AM946392) with other acetylparomamine deacetylases from S. kanamyceticus (KacA: AJ582817 or KanN: AJ628422), S. fradiae (Neo16: AJ843080 or NeoL: AB211959), Bacillus circulans (BtrD: BAE07068), Actinomadura sp. ATCC 39727 (Dbv21: AJ561198), Actinoplanes teichomyceticus (Orf2*: AJ632270), and Mycobacterium bovis AF2122/97 (MshB: NP854857). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ80% homology. Black letters in light gray boxes represent residues with Ϸ60% homology. The predicted product of gtmM (254 aa) is 29% identical to KacA, 37% identical to Neo16, 25% identical to BtrD, 28% identical to Orf2*, and 25% identical to Dbv21. However, it does not show sequence identity with MshB. The conserved sequence motifs, obtained from MshB crystallization studies (4), near the N terminus ([A/P]HXDD) and another toward the middle of the protein (HXDH) are underlined.
Fig. S6.
Sequence alignment of GtmE with other glycosyltransferases from S. kanamyceticus (KanE: GenBank accession no. CAE46941, or KanM2: CAF31591) and S. tenebrarius (TbmD: CAE22469, or TobM2: CAH18558). White letters in black boxes represent amino acid residues identical in all species, while white letters in gray boxes represent residues with Ϸ60% homology. The predicted product of gtmE is 53% identical to KanE (KanM2) and 56% identical to TbmD (TobM2). , and mass spectra of (B) authentic 1a, and (C) heterologously produced 1a from S. venezuelae strain harboring pYJ496 expressing the gtmB-gtmA-gacH genes. 
